Osmotic Agents for Nasal Polyp Dehydration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nasal polyposis, such as corticosteroid-based therapies, often cause local hypersensitivity and have limitations in long-term use, and surgical interventions are invasive and not always effective, necessitating the development of alternative approaches.
Innovation Solution
The use of osmotic agents like albumin and mannitol, potentially combined with anti-inflammatory compounds like glycyrrhizic acid, to create an osmotic gradient that reduces the inner pressure of nasal polyps, thereby alleviating symptoms and potentially delaying or replacing surgical interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroid-based therapies are used to treat nasal polyposis, then anti-inflammatory effects are achieved, but local hypersensitivity reactions occur and long-term use is limited
Solution Approach 1:
The patent introduces osmotic agents (mannitol, albumin, glycerol) as intermediary substances that create an osmotic gradient to draw water out of polyp tissue. This mediator approach achieves polyp reduction without using corticosteroids, thereby avoiding hypersensitivity reactions while maintaining therapeutic effectiveness
Solution Approach 2:
The invention changes the therapeutic parameter from pharmacological anti-inflammatory action to physical osmotic action. By using osmotic agents that create concentration gradients, the treatment achieves polyp reduction through water removal rather than inflammation suppression, eliminating corticosteroid-related side effects
2Ease of operation
If surgical intervention is performed to remove nasal polyps, then immediate symptom relief is achieved, but the treatment is invasive and not always effective in preventing recurrence
Solution Approach 1:
The patent replaces the mechanical surgical removal system with a chemical-osmotic system. Instead of physically cutting and removing polyps through surgery, the treatment uses osmotic agents to dehydrate and shrink polyps in place, eliminating surgical invasiveness while achieving symptom relief
Solution Approach 2:
The osmotic agents work by creating a concentration gradient that naturally draws water out of the polyp tissue. The treatment leverages the natural osmotic properties of the agents and the body's own fluid dynamics to achieve polyp reduction without external mechanical intervention
3Adaptability or versatility
If non steroidal anti-inflammatory drugs are used to treat nasal polyposis, then alternative anti-inflammatory therapy is provided, but real efficiency upon patients has not yet been demonstrated
Solution Approach 1:
The patent replaces pharmacological anti-inflammatory mechanisms with physical osmotic mechanisms. By using osmotic pressure gradients rather than drug-receptor interactions, the treatment provides a novel alternative therapy with a different mode of action that does not rely on demonstrated anti-inflammatory efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The osmotic agents effectively reduce nasal polyp symptoms and size without causing side effects, offering a non-invasive alternative to surgical treatments and potentially improving patient quality of life by reducing polyp mass and alleviating inflammation.
Implementation Method 1
The use of at least one osmotic agent in the seat wherein the nasal polyposis appears determines a great reduction or elimination of the symptoms and troubles associated to said pathology
Data Source
AI summary
The present invention relates to osmotic agents for use in treating nasal polyposis and to pharmaceutical compositions containing thereof.